0001554855-26-000467
SEC filing60 Degrees Pharmaceuticals achieved revenue growth in FY2025, but continued operating losses and cash burn highlight ongoing challenges in achieving sustainable profitability despite improved sales dynamics.
Despite a shortage of Arakoda 16-ct boxes beginning in April 2025—caused by delays in commercial validation of a new packaging format—domestic commercial product sales increased. This growth was driven by rising demand, price adjustments, and fewer product returns, contributing to a 65.5% year-over-year increase in revenue, reaching $1.0 million for FY2025.
Operating income improved to -$7.8M from -$9.7M in the prior year, a 20.1% year-over-year improvement, indicating reduced operating cash use despite ongoing R&D and administrative investments. Net loss also narrowed to -$7.4M from -$7.9M, with diluted EPS improving to -$11.73 from -$18.55, reflecting less severe per-share erosion. However, both metrics remain deeply negative, underscoring persistent unprofitability.
With no plans to pay dividends and limited internal cash generation, 60 Degrees remains reliant on external financing. While revenue momentum is positive, achieving gross and net profitability will require further scaling, better inventory management, and disciplined cost control. Future success hinges on securing capital to sustain operations and advance its single marketed product’s commercial viability.